Survival benefit of oral UFT for adjuvant chemotherapy after completely resected non-small-cell lung cancer

Publisher Website
Google Scholar
Abstract
7002 Background: Survival rate should be used as the primary endpoint in clinical trials assessing the response of non-small-cell lung cancer to postoperative adjuvant chemotherapy. Single studies usually do not provide clear-cut conclusions because of limited sample size. We therefore performed a meta-analysis of all properly randomized clinical trials comparing long-term adjuvant chemotherapy with UFT, an oral fluorinated pyrimidine, to surgery alone in patients with completely resected non-small-cell lung cancer, and a number of subgroup analyses and tests for interaction were performed to evaluate generalizability of drug effect. Methods:Six such trials were identified. The analysis was based on individual patient data provided by the principal investigator of each trial. Data from 2,003 eligible patients were analyzed on an intention-to-treat basis. The endpoint of interest was overall survival at 5 years after surgery. Major prognostic factors were well balanced between the UFT group and surgery alone group. Results: The results of meta-analysis demonstrated that adjuvant chemotherapy with UFT significantly improved overall survival (5-year OS, HR, 0.77; 95%CI, 0.63–0.94; p=0.011, 7-year OS, HR, 0.74; 95%CI, 0.61–0.88; p=0.001). The 5-year OS rates and 7-year OS rates were 81.8%, 76.5% for the UFT arm and 77.2%, 69.5% for the surgery alone arm. Conclusions: We conclude that postoperative adjuvant chemotherapy with UFT has a beneficial effect uniformly in patients with completely resected early-stage non-small-cell lung cancer. No significant financial relationships to disclose.

This publication has 0 references indexed in Scilit: